United States of America

Currently, thousands of hernia mesh lawsuits are pending in courts across the country. Our hernia mesh lawyers are handling these cases in all 50 states. This page:

  1. Discusses this litigation
  2. Provides the latest 2026 updates and the latest hernia mesh Bard MDL-2846 news on the settlement

This page is for women considering filing a Depo-Provera lawsuit. Our lawyers provide the latest updates, explain the litigation and settlement process, and offer our assessment of potential Depo-Provera settlement amounts.

Scientific research has found a strong association between prolonged use of injectable medroxyprogesterone acetate, the active drug in Depo-Provera, and intracranial meningioma. Women who received Depo-Provera injections and were later diagnosed with a meningioma are filing lawsuits alleging that Pfizer and related companies failed to provide an adequate warning.

Our attorneys are reviewing these cases nationwide. If you believe you may have a Depo-Provera claim, call us at 800-553-8082 or contact us online.

Uber is facing the largest wave of passenger sexual assault lawsuits in U.S. history. Survivors across the country allege that Uber drivers sexually assaulted them and that the company is legally responsible because it failed to screen drivers properly, ignored prior complaints, and did not implement basic safety measures.

These claims are now consolidated in In re: Uber Technologies Inc., Passenger Sexual Assault Litigation, MDL No. 3084, in the Northern District of California. The Judicial Panel on Multidistrict Litigation centralized these lawsuits because they share common factual questions about Uber’s knowledge of sexual assault reports, driver screening, driver training, and safety measures. This is not technically a class action lawsuit. It is an MDL where the cases are consolidated for discovery, but each victim maintains her own claim.

As of June 2026, more than 3,000 plaintiffs have joined the federal MDL, with hundreds more cases still pending in the California coordinated proceeding. The first MDL trial began in January 2026, and the jury returned an $8.5 million verdict in early February.

Our lawyers are handling Similac and Enfamil infant formula lawsuits for families whose premature babies suffered or died from necrotizing enterocolitis (NEC) after taking one of these formulas. Our law firm is reviewing NEC lawsuits in all 50 states.

Medical research links cow milk-based infant formulas such as Similac and Enfamil to a dangerous neonatal medical condition known as necrotizing enterocolitis. These newborn NEC formula lawsuits make many allegations. But at their core, they allege that the makers of these formulas knew of the risk of NEC and did nothing to warn families and give them a choice.

If your premature baby was diagnosed with NEC after being given Similac or Enfamil formula, you may be able to participate in a class action lawsuit against the formula companies and receive financial compensation for the harm that was done to your child.

Bard PowerPort lawsuits allege that defects in implanted port catheters can cause fractures, migration, blood clots, infections, embolisms, and other serious complications. Thousands of product liability lawsuits are now pending against Bard and its parent company, Becton Dickinson, in a federal multidistrict litigation in Arizona.  After a long slog, these cases are now moving forward.

The first bellwether trial ended with a partial defense verdict and a deadlocked jury on the central design defect claim. The next trial, Divelbliss v. C.R. Bard, is scheduled to begin today. It involves an alleged fracture of a silicone Groshong catheter. Five bellwether trials are now expected to run through February 2027. Our lawyers remain bullish on well-documented fracture, migration, and embolization cases.

This page provides the latest Bard PowerPort lawsuit updates, projected settlement amounts, and information about who may qualify to file a claim.

Our lawyers are reviewing hair relaxer cancer lawsuits on behalf of women throughout the United States. These claims involve women who used chemical hair relaxers or hair straighteners for years and were later diagnosed with uterine cancer, including endometrial cancer, ovarian cancer, or serious uterine fibroids that led to a hysterectomy.

The federal hair relaxer litigation now includes nearly 12,000 plaintiffs. The cases are moving through expert discovery and bellwether preparation in the Northern District of Illinois. No hair relaxer settlement has been announced, and no plaintiff has received a settlement payout through the federal MDL. The latest hair relaxer lawsuit update is that Judge Mary Rowland has lifted a discovery stay for a group of defendants after concluding that settlement discussions had not produced enough progress to justify keeping those cases frozen.

The strongest cases generally involve frequent, long-term use followed by uterine or ovarian cancer, a clear product history, and substantial treatment or reproductive injury.

This page explains the Suboxone tooth decay lawsuits, the dental injuries linked to Suboxone film, and where the federal MDL stands in 2026.

The core claim in the Suboxone litigation is straightforward: plaintiffs allege that Indivior and related defendants knew, or should have known, that Suboxone film could cause severe dental damage, including tooth decay, enamel erosion, broken teeth, tooth loss, and expensive dental reconstruction. Plaintiffs contend the companies failed to warn patients and prescribing doctors until the FDA forced a dental warning in 2022.

Our firm is not accepting new Suboxone cases in 2026. This page is provided for litigation updates and general information for victims and their families

Dupixent lawsuits are now moving forward in federal court for patients who allege the drug caused, accelerated, or unmasked cutaneous T-cell lymphoma and related T-cell lymphomas. On June 4, 2026, the Judicial Panel on Multidistrict Litigation centralized the federal Dupixent cases in MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi.

Dupixent, also known as dupilumab, is a biologic medication used to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, bullous pemphigoid, allergic fungal rhinosinusitis, and other inflammatory conditions. For many patients, Dupixent has provided real relief where other treatments failed. But for some patients, the story has been very different.

The lawsuits allege that Regeneron and Sanofi failed to warn doctors and patients that cutaneous T-cell lymphoma, often called CTCL, can mimic eczema and that Dupixent may mask, accelerate, or delay diagnosis of an underlying lymphoma. Plaintiffs argue that patients with adult-onset, atypical, or treatment-resistant dermatitis should have been warned to rule out lymphoma before starting Dupixent and to stop and investigate if symptoms worsened or changed during treatment.

Our lawyers are investigating Ozempic lawsuits for patients with NAION, gastroparesis, or gastrointestinal conditions, including bowel obstruction or cyclic vomiting syndrome.

Ozempic is the popular brand name for semaglutide, a prescription drug approved for the treatment of type 2 diabetes. As we all know, Ozempic is also commonly used as a weight management drug. Recent scientific studies have shown that taking Ozempic, particularly at higher doses, can cause gastroparesis.

Continue reading

Our lawyers are investigating gambling addiction lawsuits involving DraftKings, FanDuel, BetMGM, Caesars, ESPN Bet, Bet365, Fanatics Sportsbook, Hard Rock Bet, and other online betting platforms. The central allegation is that these companies had the data to identify compulsive gambling behavior and, instead of slowing vulnerable users down, continued to push bonus bets, deposit matches, notifications, VIP offers, profit boosts, parlays, microbets, and personalized promotions.

If you or your child suffered serious harm from online sports betting addiction, the first question is not whether gambling was legal. The first question is whether the platform used design, data, and marketing to keep a vulnerable user betting when a responsible operator should have stepped in.

If you or someone you love has suffered severe financial and emotional harm because of addiction to online gambling or sports betting, contact our lawyers at 800-553-8082 or get a free, no-obligation online consultation.

Contact Information